[Antibodies to glutamic acid decarboxylase in patients with Graves disease].
OBJECTIVE
To investigate the level and clinical implication of antibodies to glutamic acid in patients with Graves disease.


METHODS
ELISA and RIA were used to determine the decarboxylase (GADAb) levels of GADAb, thyroglobulin antibodies (TGAb), thyroidperoxidase antibodies(TPOAb), free triiodothyronine (FT3) and free thyroxine (FT4) before and after treatment in the patients with Graves disease not yet complicated by diabetes mellitus and in the healthy volunteers as controls. Then the relations of GADAb to FT3, FT4, TGAb and TPOAb were detected.


RESULTS
The correlation coefficients between GADAb and FT3, FT4 were--0.367 (P > 0.05) and 0.029 (P > 0.05), respectively. The correlation coefficients between GADAb and titers of TGAb, TPOAb were 0.320 (P > 0.05) and 0.394 (P > 0.05), respectively. The levels of GADAb, TGAb, TPOAb, and the ratio of patients with positive GADAb were reduced in the treated patients with Graves disease, but no significant difference was observed between the treated and untreated patients.


CONCLUSIONS
The above data indicated that GADAb was related to Graves disease, but no relation was seen between GADAb and thyroid
An
Zhenmei
Z
Department of Endocrinology, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhao
Hongli
H
Li
Shuangqing
S
Zhao
Guizhi
G
D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006111:Graves Disease / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D008297:Male; D013954:Thyroglobulin / Q000276:immunology
D013956:Antithyroid Agents; D001323:Autoantibodies; D015415:Biomarkers; D013954:Thyroglobulin; D005968:Glutamate Decarboxylase